和譽－Ｂ (2256.HK)

3.130 +0.020 (+0.64%) 收市：04:09PM HKT

和譽－Ｂ

Building 3
No. 898 Halei Road Zhangjiang Hi-Tech Park Pudong New Area
Shanghai
China
86 21 6891 2098
https://www.abbisko.com

版塊: Healthcare
行業: Biotechnology
全職員工: 258

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Zidong Zhang	Chief Financial Officer	無	無	1982
Ms. Huimin Tian	Head of Operations & Joint Company Secretary	無	無	無
Mr. Yongyi Li	General Counsel	無	無	1976
Ms. Jia Feng	Head of Human Resource	無	無	無
Dr. Jing Ji	Chief Medical Officer	無	無	1971
Ms. Yin Wah Chan FCCA, FCIS, FCS, HKICS	Joint Company Secretary	無	無	1975

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 HKD。

描述

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company's product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of fexagratinib and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.

公司管治

截至 無 止，和譽－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。